Chairman and CEO of Abbott Laboratories (NYSE:ABT), recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Ford ...
Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device launches and growing demand for its glucose monitors to offset a hit ...
Hosted on MSN16d
Abbott Recovers After First-Quarter Outlook Misses Estimates(Bloomberg) -- Abbott Laboratories is forecasting lower-than-expected first-quarter earnings but full-year profit in line with Wall Street estimates as the health care company points to strong demand ...
Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.2% year on year to $10.97 billion. Its non-GAAP profit ...
Abbott Laboratories will report earnings pre-market on January 22, with an earnings consensus of $1.04 per share. Abbott continues to execute growth businesses with excellent marketing and ...
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback